2008-2011 年加拿大医院分离的铜绿假单胞菌的药敏情况：CANWARD 研究。
Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011.
机构信息
Department of Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada.
出版信息
Diagn Microbiol Infect Dis. 2012 Aug;73(4):361-4. doi: 10.1016/j.diagmicrobio.2012.05.007. Epub 2012 Jun 12.
Broth microdilution (Clinical and Laboratory Standards Institute) was used to evaluate the antimicrobial susceptibility of 1549 Pseudomonas aeruginosa clinical isolates collected in Canada between January 2008 and October 2011. The percentage of isolates susceptible was as follows: amikacin 92.0%, ceftazidime 83.5%, ciprofloxacin 74.3%, colistin 93.4%, gentamicin 76.8%, meropenem 82.7%, and piperacillin-tazobactam 83.6%. Antimicrobial susceptibility did not change significantly between 2008 and 2011, with the exception of increasing susceptibility to gentamicin (P < 0.0001).
肉汤微量稀释法（临床和实验室标准协会）用于评估 2008 年 1 月至 2011 年 10 月期间在加拿大收集的 1549 株铜绿假单胞菌临床分离株的抗菌药物敏感性。敏感分离株的百分比如下：阿米卡星 92.0%、头孢他啶 83.5%、环丙沙星 74.3%、黏菌素 93.4%、庆大霉素 76.8%、美罗培南 82.7%和哌拉西林他唑巴坦 83.6%。除了对庆大霉素的敏感性增加（P<0.0001）外，2008 年至 2011 年间抗菌药物敏感性没有显著变化。
Zotero 插件